Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures.

Department of Health Services, University of Washington Seattle, Seattle, Washington, United States
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 10/2005; 294(15):1903-8. DOI: 10.1001/jama.294.15.1903
Source: PubMed

ABSTRACT Case series demonstrate that bariatric surgery can be performed with a low rate of perioperative mortality (0.5%), but the rate among high-risk patients and the community at large is unknown.
To evaluate the risk of early mortality among Medicare beneficiaries and to determine the relative risk of death among older patients.
Retrospective cohort study.
All fee-for-service Medicare beneficiaries, 1997-2002.
Thirty-day, 90-day, and 1-year postsurgical all-cause mortality among patients undergoing bariatric procedures.
A total of 16 155 patients underwent bariatric procedures (mean age, 47.7 years [SD, 11.3 years]; 75.8% women). The rates of 30-day, 90-day, and 1-year mortality were 2.0%, 2.8%, and 4.6%, respectively. Men had higher rates of early death than women (3.7% vs 1.5%, 4.8% vs 2.1%, and 7.5% vs 3.7% at 30 days, 90 days, and 1 year, respectively; P<.001). Mortality rates were greater for those aged 65 years or older compared with younger patients (4.8% vs 1.7% at 30 days, 6.9% vs 2.3% at 90 days, and 11.1% vs 3.9% at 1 year; P<.001). After adjustment for sex and comorbidity index, the odds of death within 90 days were 5-fold greater for older Medicare beneficiaries (aged > or =75 years; n = 136) than for those aged 65 to 74 years (n = 1381; odds ratio, 5.0; 95% confidence interval, 3.1-8.0). The odds of death at 90 days were 1.6 times higher (95% confidence interval, 1.3-2.0) for patients of surgeons with less than the median surgical volume of bariatric procedures (among Medicare beneficiaries during the study period) after adjusting for age, sex, and comorbidity index.
Among Medicare beneficiaries, the risk of early death after bariatric surgery is considerably higher than previously suggested and associated with advancing age, male sex, and lower surgeon volume of bariatric procedures. Patients aged 65 years or older had a substantially higher risk of death within the early postoperative period than younger patients.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bariatric surgery has been proved to be the safest and efficient procedure in treating morbid obese patients, but data is still lacking in the elderly population. The aim of our study was to compare the safety and efficacy of laparoscopic Roux-en-Y gastric bypass (LRYGB) and sleeve gastrectomy (LSG) in patients aged more than 55 years. We performed a retrospective review of a prospectively collected database. All patients with body mass index (BMI) ≧32 kg/m(2) and aged more than 55 years undergoing LRYGB or LSG in BMI Surgery Centre, E-Da Hospital between January 2008 and December 2011 with at least one year of follow up were included for the analysis. Demography, peri-operative data, weight loss and surgical complications were all recorded and analyzed. Mean age and BMI of these 68 patients (22 males and 46 female) were 58.8 years (55-79 years) and 39.5 kg/m(2) (32.00-60.40 kg/m(2)). LRYGB was performed in 44 patients and LSG in 24 patients. The two groups were comparable in their preoperative BMI, American Society of Anaesthesia (ASA) score and gender distribution. LSG patients were significantly older than patients receiving LRYGB. The proportion of type 2 diabetes preoperatively was significantly higher in LRYGB patients as compared to LSG patients (88.63% vs. 50%; P < 0.01). The prevalence of other co-morbidities was similar and comparable between the groups. Mean BMI in the LRYGB and LSG groups at the end of 1 year were 28.8 kg/m(2) and 28.2 kg/m(2), respectively, and there was no statistically significant difference in mean percentage of excess weight loss (%EWL) at 1 year. The percentage of resolution of diabetes was significantly higher in LRYGB (69.2%) as compared to LSG (33.3%). On the other hand, there was no statistical difference in the percentage of resolution of hypertension, hyperlipidemia and fatty liver hepatitis. The overall morbidity and re-operation rate was higher in LRYGB patients. In morbidly elderly patients, both surgeries achieved good weight loss and resolution of comorbidities. LRYGB is superior to LSG in terms of diabetes remission but carries higher complication rates even at high volume centres.
    04/2015; 29(2):118-24. DOI:10.7555/JBR.29.20140108
  • [Show abstract] [Hide abstract]
    ABSTRACT: To create a decision analytic model to estimate the balance between treatment risks and benefits for severely obese patients with diabetes. Bariatric surgery leads to many desirable metabolic changes, but long-term impact of bariatric surgery on life expectancy in patients with diabetes has not yet been quantified. We developed a Markov state transition model with multiple Cox proportional hazards models and logistic regression models as inputs to compare bariatric surgery versus no surgical treatment for severely obese diabetic patients. The model is informed by data from 3 large cohorts: (1) 159,000 severely obese diabetic patients (4185 had bariatric surgery) from 3 HMO Research Network sites; (2) 23,000 subjects from the Nationwide Inpatient Sample; and (3) 18,000 subjects from the National Health Interview Survey linked to the National Death Index. In our main analyses, we found that a 45-year-old woman with diabetes and a body mass index (BMI) of 45 kg/m gained an additional 6.7 years of life expectancy with bariatric surgery (38.4 years with surgery vs 31.7 years without surgery). Sensitivity analyses revealed that the gain in life expectancy decreased with increasing BMI, until a BMI of 62 kg/m is reached, at which point nonsurgical treatment was associated with greater life expectancy. Similar results were seen for both men and women in all age groups. For most severely obese patients with diabetes, bariatric surgery seems to improve life expectancy; however, surgery may reduce life expectancy for the super obese with BMIs over 62 kg/m.
    Annals of Surgery 05/2015; 261(5). DOI:10.1097/SLA.0000000000000907 · 7.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Current guidelines consider that bariatric surgery is relatively contra-indicated in elderly adults (over the age of 60).Objective To evaluate obesity-related morbidity following sleeve gastrectomy (SG) according to whether patients were over or under the age of 60.SettingA public-sector university hospital in France.Methods Forty-two patients over the age of 60 (the elderly group) were matched 1:2 with 84 patients under 60 (the control group). The primary objective was to compare weight change and the remission rate of comorbidities in the two groups after 24 months of follow-up. The secondary endpoints were short- and mid-term postoperative outcomes (operating time, the frequency of conversion to laparotomy, the length of hospital stay, postoperative complications, mortality and the SG failure rate).ResultsWe did not observe any significant differences between the elderly and control groups in terms of the mean operating time (83 minutes in both groups; p=0.90), length of stay (3.2 vs. 3.4 days, respectively; p=0.51), morbidity rate (4.7% vs. 9.5%, p=0.35) or mortality rate (0% in both groups). The mean excess weight loss was significantly lower in the elderly group than in the control group at 12 months (56.2% vs. 71.4%, respectively; p<0.01) and 24 months (51.8% vs. 73.5%, p<0.01). We observed similar, statistically significant remissions of metabolic syndrome in the elderly and control groups (95% vs. 90%, respectively; p=0.55), type 2 diabetes mellitus (87% vs. 71%, p=0.13), hypertension (81% vs. 77%, p=0.71) and dyslipidemia (94% vs. 74%, p=0.09) at 24 months after SG.Conclusion Our results demonstrate the safety and efficacy of SG for morbid obesity in patients over the age of 60. In contrast to weight loss, the long-term morbidity rate and remission of obesity-related comorbidities were similar in over-60 and under-60 patients.
    Surgery for Obesity and Related Diseases 11/2014; DOI:10.1016/j.soard.2014.11.015 · 4.94 Impact Factor


Available from